Literature DB >> 11920503

Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion.

Lisa A Di Nezza1, Aileen Misajon, Jin Zhang, Tom Jobling, Michael A Quinn, Andrew G Ostör, Guiying Nie, Alex Lopata, Lois A Salamonsen.   

Abstract

BACKGROUND: The actions of the extracellular-matrix degrading enzymes, matrix metalloproteinases (MMPs), are implicated in tumorigenesis. The cellular localization of MMP-2, MMP-9, membrane type 1 (MT1)-MMP, tissue inhibitors of metalloproteinases (TIMPs) 1-3, and the presence of active gelatinases were investigated in endometrial carcinoma.
METHODS: Endometrial carcinomas were grouped according to histologic grade (Grades 1-3), depth of myometrial invasion (0, < 50%, > 50%) and the presence of vascular/lymphatic invasion. Twenty-nine endometrial carcinoma biopsies were investigated immunohistochemically to determine the tissue localization of MMP-2 (gelatinase A), MMP-9 (gelatinase B), MT1-MMP, and TIMPs 1-3. In situ hybridization was performed to localize MMP-2 and MMP-9 mRNA. The presence of active gelatinases was assessed using in situ zymography.
RESULTS: Epithelial tumor cells were the main site of MMP-2, MMP-9, and MT1-MMP protein. Variable stromal cell localization was also observed, particularly in areas adjacent to tumor nests. Semiquantitative analysis revealed increases in MMP-9 and MMP-2 but not MT1-MMP staining scores in tumor epithelial cells in the transition from histologic Grade 1 to Grades 2 and 3. Matrix metalloproteinase-9 and MT1-MMP staining scores in tumor cells were significantly associated with the presence of myometrial invasion and vascular/lymphatic invasion, while MMP-2 did not correlate with these factors. In addition, MT1-MMP was co-localized with MMP-2, supporting its role in the activation of proMMP-2. Tumor cells from all histologic grades stained intensely for TIMP-2 and TIMP-3 proteins, while variable stromal staining was observed. In Grade 1 carcinomas TIMP-1 was predominantly immunolocalized to the stromal compartment with variable tumor cell localization being observed in Grades 2 and 3 carcinomas. Matrix metalloproteinase-9 and MMP-2 mRNAs were predominantly observed in tumor epithelial cells as well as in the stroma to varying degrees. In situ zymography revealed active forms of gelatinases at the cellular surface and in association with tumor epithelial cells within endometrial carcinoma tissues.
CONCLUSIONS: These data suggest that increasing expression of MMPs and endometrial carcinoma progression are closely related. Active gelatinases are present in endometrial carcinoma, resulting in alterations to the microenvironment that promote tumor invasion and metastasis. Copyright 2002 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11920503     DOI: 10.1002/cncr.10355

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  45 in total

1.  Membrane type-1 matrix metalloproteinase (MT1-MMP) correlates with the expression and activation of matrix metalloproteinase-2 (MMP-2) in inflammatory breast cancer.

Authors:  Diaa Al-Raawi; Helal Abu-El-Zahab; Mohamed El-Shinawi; Mona Mostafa Mohamed
Journal:  Int J Clin Exp Med       Date:  2011-10-11

2.  Estrogen suppresses expression of the matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs (RECK) within the mouse uterus.

Authors:  Xuan Zhang; Caitlin Healy; Warren B Nothnick
Journal:  Endocrine       Date:  2012-08       Impact factor: 3.633

3.  ETS-1 protein regulates vascular endothelial growth factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian carcinoma cell line SKOV-3.

Authors:  Sonali Ghosh; Moitri Basu; Sib Sankar Roy
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

4.  Matrix metalloproteinases 2 and 9 in oral squamous cell carcinomas: manifestation and localization of their activity.

Authors:  Keizo Kato; Akira Hara; Toshiya Kuno; Nami Kitaori; Zhi Huilan; Hideki Mori; Makoto Toida; Toshiyuki Shibata
Journal:  J Cancer Res Clin Oncol       Date:  2004-12-22       Impact factor: 4.553

Review 5.  Regulation of uterine matrix metalloproteinase-9 and the role of microRNAs.

Authors:  Warren B Nothnick
Journal:  Semin Reprod Med       Date:  2008-10-24       Impact factor: 1.303

6.  Prostaglandin E2 receptor EP1 phosphorylate CREB and mediates MMP2 expression in human cholangiocarcinoma cells.

Authors:  Bo Sun; Rong Rong; Hai Jiang; Hai Zhang; YiPin Wang; Xiaoming Bai; Min Zhang; Juan Ma; Shukai Xia; Wei Shu; Li Zhang; Jing Leng
Journal:  Mol Cell Biochem       Date:  2013-03-15       Impact factor: 3.396

7.  Regulated expression of matrix metalloproteinases, inflammatory mediators, and endometrial matrix remodeling by 17beta-estradiol in the immature rat uterus.

Authors:  Louise A Russo; Bryan J Peano; Shreya P Trivedi; Todd D Cavalcanto; Benjamin A Olenchock; Joseph A Caruso; Amanda R Smolock; Oleg Vishnevsky; Russell M Gardner
Journal:  Reprod Biol Endocrinol       Date:  2009-11-04       Impact factor: 5.211

8.  Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines.

Authors:  Andrea Schröpfer; Ulrike Kammerer; Michaela Kapp; Johannes Dietl; Sonja Feix; Jelena Anacker
Journal:  BMC Cancer       Date:  2010-10-13       Impact factor: 4.430

9.  Effect of troglitazone on tumor growth and pulmonary metastasis development of the mouse osteosarcoma cell line LM8.

Authors:  Junichi Aizawa; Kenshi Sakayama; Setsuya Kamei; Teruki Kidani; Haruyasu Yamamoto; Yoshiaki Norimatsu; Hiroshi Masuno
Journal:  BMC Cancer       Date:  2010-02-22       Impact factor: 4.430

10.  Eutopic endometrium and peritoneal, ovarian and bowel endometriotic tissues express a different profile of matrix metalloproteinases-2, -3 and -11, and of tissue inhibitor metalloproteinases-1 and -2.

Authors:  Catherine Uzan; Annie Cortez; Charlotte Dufournet; Raffaèle Fauvet; Jean-Pierre Siffroi; Emile Daraï
Journal:  Virchows Arch       Date:  2004-09-28       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.